The stock market is full of unproven, speculative stocks that aren't suitable for the average investor. However, if you're aware of company-specific risks and willing and able to accept the consequences, speculative stocks can occasionally turn out to be big winners for a portfolio. With that in mind, the Fool's health care bureau chief, Brenton Flynn, outlines two of 2013's best-performing (and speculative) stocks in the industry and offers a few words of caution to prospective buyers.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
2 Speculative Stocks Soaring in 2013
NASDAQ: PACB
Pacific Biosciences Of California

Pacific BioSciences and Peregrine are soaring, but buyer beware...
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Illumina and Pacific Biosciences of California. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.